The panoramic picture of pepsinogen gene family with pan-cancer

Shixuan Shen1,2,3 | Hao Li1,2,3 | Jingwei Liu1,2,3 | Liping Sun1,2,3 | Yuan Yuan1,2,3

Abstract

**Background:** It is well known that pepsinogen (PGs), as an important precursor of pepsin performing digestive function, has a good correlation with the occurrence and development of gastric cancer and it is also known that ectopic PGs expression is related to the prognosis of some cancers. However, the panoramic picture of pepsinogen gene family in human cancer is not clear. This study focused on elucidating the expression profile, activated pathway, immune cells infiltration, mutation, and copy number variation of PGs and their potential role in human cancer.

**Method:** Based on the next generation sequence data from TCGA, Oncomine, and CCLE, the molecular changes and clinical correlation of PGs in 33 tumor types were analyzed systematically by R language, including the expression, mutation, and copy number variation of PGs and their correlation with cancer-related signal transduction pathway, immune cell infiltration, and prognostic potential in different cancers.

**Results:** PGs expression profiles appear different in 33 tumors. The transcriptional expression of PGs was detected in 16 of all 33 tumors. PGC was highly expressed in cholangiocarcinoma, colon adenocarcinoma, rectum adenocarcinoma, uterine corpus endometrial carcinoma, bladder urothelial carcinoma and breast cancer, while decreased in stomach adenocarcinoma, kidney renal clear cell carcinoma, prostate adenocarcinoma, lung squamous cell carcinoma, and esophageal carcinoma. PGA3, PGA4, and PGA5 were expressed in most normal tissues, but decreased in cancer tissues. PGs expression was significantly related to the activation or inhibition of many signal transduction pathways, in which PGC and PGA5 are more likely to be associated with cancer-related pathways. PGC participated in 33 regulatory network pathways in pan-cancer, mainly distributed in stomach adenocarcinoma, esophageal carcinoma, and lung squamous cell carcinoma, respectively. PGC and PGA3 expression were significantly correlated with immune cell infiltration. The results of survival analysis showed that different PGs expression play significantly different prognostic roles in different cancers. PGC was correlated with poor survival in brain lower grade glioma, skin cutaneous melanoma, and higher survival in kidney renal clear cell carcinoma, acute myeloid leukemia, mesothelioma, and uveal melanoma. PGA4 was only associated with higher survival in kidney renal clear cell carcinoma.
1 | INTRODUCTION

The Cancer Genome Atlas (TCGA) has been well known and widely used. As its final work, the Pan-Cancer Atlas is getting to know well, which made a multigroup integrated analysis in the aspects of Cell Origin Patterns, Oncogenic Processes, and Tumor Signaling Pathways (http://www.cell.com/pb-assets/consortium/pancanceratlas/pancani3/index.html) and provides a referential idea for us to study cancer from the point of view of broad-spectrum molecular characteristics. Through pan-cancer analysis, we learned that tumors that occurred in different organs with the same histomorphological type, such as squamous cell carcinoma of the head, neck, lungs, esophagus, bladder, and cervix, had strong molecular similarity. There are also molecular similarities in cancers with similar anatomical structure but different location, such as gastric cancer, colon cancer, and rectal cancer. On the contrary, some cancers occur in the same organ, but may belong to completely different molecular subtypes, such as kidney cancer. The findings mentioned above suggest that a comprehensive longitudinal analysis of the panoramic picture of certain molecular events in a variety of tumors can identify the mutual molecular characteristics among many kinds of human cancers, which can provide new insights into the clinical feasibility of comprehensive cancer therapy and the development of new targeted and combined therapies.

Pepsinogen gene family (PGs) are important precursors of pepsin that performs digestive function in stomach, and they belong to the family of aspartate proteolytic enzymes. According to the immunological and biochemical characteristics, PGs can be divided into two types: PGA and PGC. Among them, PGA can be further divided into three subtypes of PGA3, PGA4, and PGA5. PGs are mainly synthesized by the chief cells of gastric mucosa, stored in zymogen granules at rest, secreted into the gastric cavity once receiving physiological or external chemical signals, and activated into pepsin in the acidic environment of gastric juice. It is traditionally believed that PGs are the final products of the differentiation and maturation of gastric mucosal cells and the sign of the gradual maturity of digestive function. Previous studies have confirmed that the expression of PGs have a good correlation with the occurrence of gastric cancer, which could be used as biomarkers for screening gastric cancer and its precursors. In addition to in situ expression in gastrointestinal tissues, PGs is also expressed in a few tissues outside the gastrointestinal tract, such as PGC in normal seminal vesicles and lung type II epithelial cells. Interestingly, recent studies have found that PGC can be ectopic expressed in tumor tissues that were not expressed initially, such as prostate cancer, breast cancer, ovarian cancer, endometrial cancer, pancreatic cancer, kidney cancer, bladder cancer, eyelid basal cell carcinoma, squamous cell carcinoma, melanoma, and so on. PGs was expressed unevenly in a variety of cancer tissues and was related to many carcinogenic pathways and involved in the immune regulation. PGC participated in 33 regulatory pathways in human cancer. Different PGs expression play significantly different prognostic roles in different cancers. The variation of copy number of PGC gene could affect the PGC expression. These findings suggested that PGs, especially PGC have characteristic of broad-spectrum expression in multiple cancers rather than being confined to the gastric mucosa, which may made PGs be useful biomarkers for prediction/diagnosis/prognosis and effective targets for treatment in human cancer.

**KEYWORDS**
copy number, expression, immune cell, mutation, pan-cancer, pathways, pepsinogen, prognosis, risk

Genetic variation analysis showed that PGC gene often mutated in uterine corpus endometrial carcinoma and stomach adenocarcinoma had extensive copy number amplification in various tumor types. PGC expression was upregulated with the increase of copy number in cholangiocarcinoma, esophageal carcinoma, and kidney renal papillary cell carcinoma, while in stomach adenocarcinoma, PGC was upregulated regardless of whether the copy number was increased or decreased.

**Conclusions:** PGs was expressed unevenly in a variety of cancer tissues and was related to many carcinogenic pathways and involved in the immune regulation. PGC participated in 33 regulatory pathways in human cancer. Different PGs expression play significantly different prognostic roles in different cancers. The variation of copy number of PGC gene could affect the PGC expression. These findings suggested that PGs, especially PGC have characteristic of broad-spectrum expression in multiple cancers rather than being confined to the gastric mucosa, which may made PGs be useful biomarkers for prediction/diagnosis/prognosis and effective targets for treatment in human cancer.
regarding to PG gene family in human cancer remains to be further explored.

In this study, by using the multilevel data from TCGA based Pan-Cancer Atlas, Oncomine and Cancer Cell Line Encyclopedia (CCLE), we focused on the elucidating expression profile, activated pathway, immune cells infiltration, mutation, and copy number variation of PGs and their prediction/diagnosis/prognosis potential in pan-cancer.

2 | MATERIALS AND METHODS

2.1 | Data collection

2.1.1 | TCGA data collection

We totally collected the information of 33 different kinds of tumors in TCGA database (http://cancergenome.nih.gov/), including the information of TPM (Transcripts Per Kilobase Million) expression, mutation, and copy number variation. The clinical information (survival status, stages, grades, and survival time) were download from UCSC XENA (https://xenabrowser.net/).

TCGA data sources include all 33 different tumor types including adrenocortical carcinoma (ACC); bladder urothelial carcinoma (BLCA); breast cancer (BRCA); cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC); cholangiocarcinoma (CHOL); colon adenocarcinoma (COAD); lymphoid neoplasm diffuse large b-cell lymphoma (DLBC); esophageal carcinoma (ESCA); glioblastoma multiforme (GBM); head and neck squamous carcinoma (HNSC); kidney chromophobe (KICH); kidney renal clear cell carcinoma (KIRC); kidney renal papillary cell carcinoma (KIRP); acute myeloid leukemia (LAML); brain lower grade glioma (LGG); liver hepatocellular carcinoma (LIHC); lung adenocarcinoma (LUAD); lung squamous cell carcinoma (LUSC); mesothelioma (Meso); ovarian serous cystadenocarcinoma (OV); pancreatic adenocarcinoma (PAAD); pheochromocytoma and paraganglioma (PCPG); prostate adenocarcinoma (PRAD); rectum adenocarcinoma (READ); sarcoma (SARC); skin cutaneous melanoma (SKCM); stomach adenocarcinoma (STAD); testicular germ cell tumors (TGCT); thyroid carcinoma (THCA); thymoma (THYM); uterine corpus endometrial carcinoma (UCEC); uterine carcinosarcoma (UCS); uveal melanoma (UVM). The information of tumor and its control group can be found in Table S1.

2.1.2 | Oncomine data collection

Oncomine, a cancer microarray database and a Web-based data mining platform, was used for validation analysis, in order to facilitate discovery from TCGA.

2.1.3 | Proteomics data collection

The protein expression data of PGs gene are derived from the Protein Atlas data set (https://www.proteinatlas.org/) including 21 kinds of cancers and the corresponding normal tissues.

2.1.4 | Cellular data collection

CCLE database (https://portals.broadinstitute.org/ccle) was used to identify the PGs expression, mutation, and copy number variation in different cancer cell lines, including all 431 cell lines from six cancer types.

2.2 | Multidimensional analysis of the expression of PG gene family in pan-cancer

2.2.1 | Analysis of the expression characteristics of PGs in pan-cancer

Deseq2 package in R was used to identify differentially expressed PGs in each cancer type. The genes with adjusted \( p < 0.05 \) and at least twofold expression change (\( |\log FC| \geq 2 \)) were identified as PGs expression difference. In oncomine analysis, we also selected \( |\log FC| \geq 2, p < 0.05, \) and top 10% gene rank as threshold.

CCLE was used to identify the alternation of the expression of PGs in different cancer cell lines. Kruskal-Wallis rank test was used to compare the expression of PGs in different types of cancer cell lines.

2.2.2 | Analysis of PGs expression related signal transduction pathway in pan-cancer

Gene set variation analysis (GSVA), which is a nonparametric method to estimate gene set enrichment variation through expression data set samples, was used to calculate the correlation between tumor marker-related pathways and PGs expression. We calculated the Pearson correlation coefficient (PCC) between the PGs expression and the pathway activity to certify the PGs related to the activation or inhibition of a certain pathway. The regulatory pathway with \(|PCC| > 0.3\) and adjusted \( p < 0.05 \) has been identified as a significantly correlation.

2.2.3 | Correlation analysis of PGs expression with immune cell infiltration in pan-cancer

In order to explore the relationship between PGs and immune cell infiltration, we calculated the Spearman correlation
coefficient (SCC) between PGs expression and immune infiltrating cells. The regulatory pathway with $|SCC| > 0.3$ and adjusted P-value $< 0.05$ were identified as a significantly correlation.

2.2.4 Correlation analysis of PGs expression with prognosis in pan-cancer

To explore whether the expression of PGs was associated with the survival of different cancer patients, we divided all cancer patients into two groups according to the median of PGs expression. The survival rates between the two groups were compared by logarithmic rank test. $p < 0.05$ was statistically significant.

2.3 Analysis of PGs mutation and copy number variation in pan-cancer

2.3.1 Analysis PGs mutation in pan-cancer

The mutation data of PGs were from both TCGA and CCLE database. The mutation frequency of PGs in each cancer tissue and cell lines was defined as the proportion of mutation in the gene.

2.3.2 Analysis PGs copy number variation in pan-cancer

The Copy number variation (CNV) data of PGs in different cancers and cell lines was downloaded from TCGA and CCLE database. The frequency of CNV in each cancer type and cell lines was calculated as the proportion of CNV amplification and deletion.

2.4 Correlation analysis of PGs mutation, copy number variation, and PGs expression

The relationship between PGs mutation, copy number variation, and PGs expression was analyzed by Mann-Whitney U test in R software.

3 RESULTS

3.1 PGs expression profile in pan-cancer

3.1.1 PGs expression at mRNA level

Using the count data of 33 human tumors covered by TCGA, we analyzed the differential expression of PG family genes including PGC, PGA3, PGA4, and PGA5 in different cancers at the overall level based on continuous variable analysis. The results showed that the PGs expression profiles appear different in 33 tumors. PGC expression was higher in cholangiocarcinoma, colon adenocarcinoma, rectum adenocarcinoma, bladder urothelial carcinoma, uterine corpus endometrial carcinoma, and breast cancer but lower in kidney renal clear cell carcinoma, prostate adenocarcinoma, lung squamous cell carcinoma, stomach adenocarcinoma, and esophageal carcinoma. The expression of PGA3 and PGA4 increased in kidney renal clear cell carcinoma but decreased in thyroid carcinoma and stomach adenocarcinoma. PGA5 expression was higher in kidney renal clear cell carcinoma and kidney renal papillary cell carcinoma, but lower in stomach adenocarcinoma, esophageal carcinoma, cholangiocarcinoma, colon adenocarcinoma, uterine corpus endometrial carcinoma, prostate adenocarcinoma, breast cancer, kidney chromophobe, and thyroid carcinoma (Figure 1A). The differential expression of PGC gene in each cancer was visualized in Figure 1B. In addition, we further compared differential expression between cancer and normal tissues based on categorical variable analysis. When $\text{TPM} = \text{median value}$ was used as the cut-off value, PGC was highly expressed in hepatocellular carcinoma, colon adenocarcinoma, rectum cancer, and cholangiocarcinoma; and lowly expressed in lung squamous cell carcinoma, lung adenocarcinoma, kidney chromophobe, and kidney renal papillary cell carcinoma. When $\text{TPM} = 6$ was used as the cutoff value, PGC was highly expressed in hepatocellular carcinoma and lowly expressed in lung squamous cell carcinoma, lung adenocarcinoma, and esophageal cancer (Tables S2 and S3).

After that, we selected three well-studied cancer types including stomach adenocarcinoma, lung squamous cell carcinoma, and colorectal adenocarcinoma among 33 types of tumors from Oncomine database and conducted further analysis, to verify our TCGA findings and predict cancer risk. The results showed that in stomach adenocarcinoma and lung squamous cell carcinoma, high expression of PG is a protective factor, and high expression can reduce the risk of cancer. However, high expression in colorectal adenocarcinoma suggests an increased risk of cancer. These results were consistent with our TCGA findings (Figure S1).

3.1.2 PGs expression at protein level

The data of 21 kinds of cancers from The Protein Atlas showed that the expression of PGA3, PGA4, and PGA5 could not be detected in any cancer tissues. Only a small amount of PGC expression was detected in lung, prostate, gastric, and thyroid tissues (Figure 2). PGC protein
expression was higher in lung adenocarcinoma, and prostate adenocarcinoma but lower in stomach adenocarcinoma; but in other tissues, PGA protein was not detected. Based on the immunohistochemical results of the protein map database, we showed the protein expression of PG gene in different cancer types (Figure 3). The immunohistochemical results representing the expression of PGC protein are shown in Figure 4.

### 3.1.3 PGs expression at cell level

The CCLE analysis results showed that there was certain degree of PG expression in breast cancer, liver cancer, colorectal cancer, gastric cancer, ovarian cancer, and lung cancer cell lines (Figure 5). PGC was mainly expressed in gastric cancer, colorectal cancer, and liver cancer cell lines (Figure 6). PGA3 and PGA5 are mainly expressed in ovarian cancer
and lung cancer, while PGA4 is mainly expressed in lung cancer and gastric cancer cell lines.

3.2 | The activated transduction pathways related to PGs expression in pan-cancer

To clarify the molecular significance of PG gene family in tumorigenesis, we analyzed and visualized the relationship between the PGs expression and cancer-related transduction pathway. The results show that PGs expression was significantly related to the activation or inhibition of many carcinogenic pathways (Figure 7A), in which PGC and PGA5 are more likely to be associated with carcinogenic processes. PGC was mainly involved in K-RAS signaling pathway, bile acid metabolism, androgen response, estrogenic response, blood coagulation, and angiogenesis. PGA3, PGA4, and PGA5 are mainly involved in K-RAS signaling pathway, bile acid metabolism, mitotic G2 M phase, and other cancer-related pathways. PGA5 not only participates in the above pathways, but also participates in the mTOR pathway and DNA repair. The specific degree of correlation between the PGs expression and each cancer-related pathway is summarized in Figure 7B. The correlation coefficient between PGs and cancer-related pathways is shown in Table 1.

The above results suggested that PGC was mainly involved in cancer-related pathways. Therefore, we further analyzed and visualized the relationship between PGC and cancer-related pathways in order to further clarify the molecular significance of PGC gene in pan-tumorigenesis. The results showed that PGC participated in 33 regulatory network pathways in pan-cancer ($p < 0.05$, $R > 0.24$), mainly distributed in stomach adenocarcinoma, esophageal carcinoma, and lung squamous cell carcinoma, respectively. The stomach adenocarcinoma-related pathways involved by PGC mainly include K-RAS signal pathway, bile acid metabolism pathway, androgen response, blood coagulation process, estrogen response, and so on. The esophageal carcinoma-related pathways...
included K-RAS signal pathway, DNA repair, p53 pathway, protein secretion, TGF β signal pathway, WNT-β catenin signal pathway, and so on. The LUSC-related pathways included DNA repair, IL6-JAK-STAT3 signaling pathway, inflammation, p53 pathway, and oxidative phosphorylation. The distribution and correlation degree of all cancer-related pathways associated with PGC are shown in Table 2.

### 3.3 Correlation of PGs expression with tumor immune cells infiltration in pan-cancer

In this study, we explored the relationship between PGs expression and immune cells infiltration in pan-cancer. The results showed that the immune cells most related to PGs included B cells, mast cells, follicular helper T cells (TFH cells), and helper T cells. PGC and PGA3 were significantly correlated with immune cell infiltration (Figure 8). The coefficient of the correlation between PGs and immune cell infiltration showed that the immune genes related to the PGs are PTGDR2, SULT1C2, HDC, HPGDS, B3GAT1, and TPSAB1 (Table S4).

### 3.4 Correlation between PGs expression and prognosis in pan-cancer

The prognostic significance of PGs in different cancer were analyzed by cox regression. The results showed that PGC was associated with higher survival rate in brain lower grade glioma, skin cutaneous melanoma, and poor survival rate in kidney renal clear cell carcinoma, acute myeloid leukemia, mesothelioma, and uveal melanoma. PGA4 is only associated with higher survival rate in kidney renal clear cell carcinoma. PGA5 is related to the prolongation of survival time of cancer patients in kidney renal clear cell carcinoma and kidney renal papillary cell carcinoma, while it is related to the shortening of survival time of cancer patients in lung squamous cell carcinoma, prostate adenocarcinoma, and uterine corpus endometrial carcinoma. Different PGs expression play significantly different prognostic roles in different types of cancer (Figure 9A). Furthermore, we drew a forest map in which PGC
showed different prognostic correlations in different types of cancers (Figure 9B).

### 3.5 Characteristics of genetic variation of PGs in pan-cancer

Using the TCGA database, we analyzed the mutation frequency of PGs. The results showed that PGC gene mutations frequently occurred in uterine corpus endometrial carcinoma and stomach adenocarcinoma (Figure 10A). The overall average mutation rate is 0-5.3%. The mutation rates of PGA3, PGA4, and PGA5 in all cancer lines were low and less than 2%. In addition, we also analyzed the copy number variation (CNV) of PGs in different cancer cells (Figure 10B). PGC gene showed extensive copy number amplification in various cancer cells and decreased copy number only in kidney chromophobe. PGA3, PGA4, and PGA5 showed more copy number amplification in lung adenocarcinoma, esophageal carcinoma, kidney chromophobe, and copy number reduction in bladder urothelial carcinoma, lung squamous cell carcinoma, rectum adenocarcinoma, and cholangiocarcinoma.

In addition, CCLE database analysis revealed the mutation status of PGs in different human cancer cell lines, which showed that there were frequent mutations of PGs in colorectal cancer and gastric cancer cell lines (Figure 11).

### 3.6 Correlation between PGs mutation, copy number variation, and PGs expression

In order to explore whether PGC self-variation affects its expression, we analyzed the correlation between PGs mutation, CNV, and PGs expression. The results showed that PGs mutations did not affect the PGs expression in all cancers. Except for PGC, the CNV of PGA3, PGA4, and PGA5 had no effect on their gene expression. PGC expression was upregulated with the increase of copy number in cholangiocarcinoma, esophageal carcinoma, and kidney renal papillary cell carcinoma, while in stomach adenocarcinoma, PGC was upregulated regardless of whether the copy number was increased or decreased. The effect of copy number of PGC gene on the PGC expression is shown in Table 3.

### 4 DISCUSSION

In this study, we used the multilevel data of TCGA, Oncomine, and CCLE to reveal the expression and activated pathways, mutation, and copy number variation, prognostic potential of PGs in all 33 types of tumors and 431 cell lines, aiming to clarify the important role of PGs in tumorigenesis and development of cancers. The results suggest that there was differential expression of PGs between many kinds of cancer tissues and corresponding normal tissues, which is related to the prognosis of patients; PGs expression was closely associated with the activation of cancer-related pathways and immune cell infiltration; the copy number variation of PGC could affect the gene expression. To our knowledge, this study first drew a panoramic picture of pepsinogen gene family in human cancer.

In this study, a multidimensional analysis of PGs expression in pan-cancer based on TCGA data was conducted at mRNA, protein, and cell level, respectively. The mRNA expression of PGs was detected in 16 of all 33 kinds of tumors, while PGs was not detected in another 17 tumors. Among the 16 cancers with PGs positive expression, PGs was unevenly expressed with different levels in different cancers (Figure 1). At the protein expression level, only a small amount of PGs expression was detected in lung cancer, prostate cancer, and thyroid carcinoma, but no PGA expression was detected. At the cell detection level, there was certain degree of PGs expression in breast cancer, liver cancer, colorectal cancer, gastric cancer, ovarian cancer, and lung
| Pathway                                             | Correlation coefficient | PGC  | PGA5  | PGA3  | PGA4  |
|-----------------------------------------------------|-------------------------|------|-------|-------|-------|
| HALLMARK_ADIPOGENESIS                               | 0.104074                | 0.072013 | 0.059938 | 0.088963 |
| HALLMARK_ALLOGRAFT_REJECTION                        | 0.073248                | 0.046939 | 0.082432 | 0.13315 |
| HALLMARK_ANDROGEN_RESPONSE                          | 0.258346                | 0.065494 | 0.124837 | 0.094096 |
| HALLMARK_ANGIOGENESIS                                | 0.232618                | 0.249746 | 0.189061 | 0.165817 |
| HALLMARK_APICAL_JUNCTION                            | 0.121867                | 0.146654 | 0.091354 | 0.13103 |
| HALLMARK_APICAL_SURFACE                              | 0.179791                | 0.218459 | 0.173584 | 0.184061 |
| HALLMARK_APOPTOSIS                                   | 0.047602                | 0.045279 | 0.066674 | 0.082117 |
| HALLMARK_BILE_ACID_METABOLISM                        | 0.307126                | 0.260051 | 0.25485 | 0.253188 |
| HALLMARK_CHOLESTEROL_HOMEOSTASIS                     | 0.213147                | 0.131716 | 0.098256 | 0.175383 |
| HALLMARK_COAGULATION                                 | 0.259254                | 0.239252 | 0.161715 | 0.217216 |
| HALLMARK_COMPLEMENT                                  | 0.095378                | 0.13422 | 0.116431 | 0.12946 |
| HALLMARK_DNA_REPAIR                                  | 0.16514                 | 0.20049 | 0.16615 | 0.09401 |
| HALLMARK_E2F_TARGETS                                 | 0.25135                 | 0.29814 | 0.24509 | 0.21817 |
| HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION          | 0.00166                 | 0.061258 | 0.010087 | 0.019819 |
| HALLMARK_ESTROGEN_RESPONSE_EARLY                     | 0.242907                | 0.166006 | 0.150116 | 0.166 |
| HALLMARK_ESTROGEN_RESPONSE_LATE                      | 0.213013                | 0.153224 | 0.105702 | 0.145089 |
| HALLMARK_FATTY_ACID_METABOLISM                       | 0.111987                | 0.06063 | 0.081834 | 0.104381 |
| HALLMARK_G2M_CHECKPOINT                              | 0.26701                 | 0.30841 | 0.2584 | 0.23313 |
| HALLMARK_GLUCOSEAAF                                | 0.134493                | 0.016814 | 0.040321 | 0.06998 |
| HALLMARK_HEDGEHOG_SIGNALING                          | 0.120912                | 0.123243 | 0.07334 | 0.102322 |
| HALLMARK_HEME_METABOLISM                             | 0.074388                | 0.111684 | 0.093911 | 0.095899 |
| HALLMARK_HYPOXIA                                    | 0.067271                | 0.12587 | 0.087012 | 0.079801 |
| HALLMARK_IL2_STAT5_SIGNALING                         | 0.137145                | 0.13121 | 0.123792 | 0.131418 |
| HALLMARK_IL6_JAK_STAT3_SIGNALING                    | 0.176787                | 0.183303 | 0.135724 | 0.149932 |
| HALLMARK_INFLAMMATORY_RESPONSE                       | 0.138655                | 0.139786 | 0.135577 | 0.134099 |
| HALLMARK_INTERFERON_ALPHA_RESPONSE                   | 0.044547                | 0.02577 | 0.013675 | 0.027553 |
| HALLMARK_INTERFERON_GAMMA_RESPONSE                   | 0.069933                | 0.034519 | 0.069113 | 0.105927 |
| HALLMARK_KRAS_SIGNALING_DN                          | 0.339758                | 0.34074 | 0.289109 | 0.322171 |
| HALLMARK_KRAS_SIGNALING_UP                          | 0.1654                  | 0.146907 | 0.163549 | 0.169164 |
| HALLMARK_MITOCELL_SPINDLE                           | 0.09698                | 0.14517 | 0.15048 | 0.14056 |
| HALLMARK_MTORC1_SIGNALING                           | 0.18071                 | 0.25302 | 0.1992 | 0.14975 |
| HALLMARK_MYC_TARGETS_V1                             | 0.24327                 | 0.26186 | 0.19809 | 0.16793 |
| HALLMARK_MYC_TARGETS_V2                             | 0.23571                 | 0.28542 | 0.2638 | 0.20025 |
| HALLMARK_MYOGENESIS                                 | 0.148353                | 0.227962 | 0.158631 | 0.201877 |
| HALLMARK_NOTCH_SIGNALING                            | 0.039809                | 0.023217 | 0.018902 | 0.039152 |
| HALLMARK_OXIDATIVE_PHOSPHORYLATION                   | 0.01812                 | 0.01984 | 0.030688 | 0.047726 |
| HALLMARK_P53_PATHWAY                                 | 0.03243                 | 0.08171 | 0.04491 | 0.03136 |
| HALLMARK_PANCREAS_BETA CELLS                        | 0.320524                | 0.303613 | 0.340141 | 0.296361 |
| HALLMARK_PEROXISOME                                  | 0.00907                 | 0.0782 | 0.03897 | 0.00352 |
| HALLMARK_PI3K_AKT_MTOR_SIGNALING                     | 0.04893                 | 0.03759 | 0.00983 | 0.00939 |
| HALLMARK_PROTEIN_SECRETION                          | 0.126021                | 0.01117 | 0.009543 | 0.020547 |
| HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY             | 0.065843                | 0.021639 | 0.049905 | 0.098622 |
| HALLMARK_SPERMATOGENESIS                             | 0.01038                 | 0.044703 | 0.057758 | 0.047252 |
cancer cell lines. Validation results based on three well-studied cancer types including stomach adenocarcinoma, lung squamous cell carcinoma, and colorectal adenocarcinoma from Oncomine database were consistent with our TCGA findings. By retrieving published literature, we also found supporting evidence that the expression of PGC in situ in gastric mucosa has a good correlation with the occurrence and development of stomach adenocarcinoma, and it is an ideal “negative marker” for stomach adenocarcinoma.\(^{1,5,14,15}\) Beside, PGC also have close relationship with ovarian cancer,\(^{16}\) breast cancers,\(^{10,17}\) and prostatic cancer.\(^{8,18}\) PGA is expressed in esophageal squamous cell carcinoma.\(^{11}\) In this study, through pan-cancer analysis, a panoramic view of PGs expression profile in all human cancers was first showed up and the results suggest that PGs, especially PGC, have characteristic of broad-spectrum expression in multiple cancers, which may made PGs be useful biomarkers for prediction/diagnosis/prognosis and effective targets for treatment in human cancer, which is an interesting and new research topic in the relevant fields.

The correlation analysis between PGs expression and cancer signal transduction pathway showed that 50 cancer-related pathways were associated with PGs expression in 33 cancers, such as K-RAS signal pathway, bile acid metabolism pathway, amino acid metabolism pathway, androgen and estrogen response pathway, mitosis, DNA repair pathway and angiogenesis. Different PGs expression have been found to be associated with different cancer-related pathways, indicating that different PGs in the same pepsinogen family have different functional effects. Among them, PGC and PGA5 are more likely to be related to the carcinogenic process. It is reported that PGC was highly expressed in breast cancer.\(^{19}\) The results of this study show that PGC was closely related to androgen response pathway and estrogen response pathway, suggesting that PGC participates in hormone-related pathways and plays a regulatory role in the occurrence and development of breast cancer. In addition, it is of particular note that PGC was involved in 33 signal pathways, mainly in three cancers including stomach adenocarcinoma, esophageal carcinoma and lung squamous cell carcinoma. According to the literature, the synthesis of pepsin can happen in Barrett’s esophagus and early esophageal carcinoma. The loss of pepsinogen in advanced esophageal squamous cell carcinoma indicates that pepsin is involved in the process of protein synthesis in the esophagus and causes esophageal carcinogenesis.\(^{20,21}\) The results of this study further confirmed that PGC is involved in the regulation of esophageal carcinoma. Both lung tissue and gastric mucosa have the same function of producing pepsinogen molecules,\(^{11}\) and the injury of normal lung tissue could increase the synthesis of pepsinogen C.\(^{22}\) Some studies have also suggested that the existence of pepsin in respiratory biological samples was caused by gastroesophageal reflux associated lung inhalation.\(^{23}\) Another study has been reported that there was a certain degree of PG expression in lung type 2 epithelial cells.\(^{24}\) The results of this study showed that the activation pathways with PGs expression is associated with the lung squamous cell carcinoma. Further research should more accurately evaluate the expression of pepsinogen and its dynamic changes in the occurrence and development of lung squamous cell carcinoma. All in all, the results mentioned above indicate that PGs family, especially PGC, may participate in the signal transduction pathways during the occurrence and development of multiple cancers and may play a synergistic role in the process.

The correlation analysis between PGs expression and tumor immune cell infiltration in pan-cancer showed that the immune infiltrating cells related to PGs included B cells, mast cells, TFH cells, and helper T cells. At present, there are few studies on the relationship between PGs and immune cell infiltration. Al-Ezzy et al found that the secretion of PGA and PGC was related to the immune response of Helicobacter pylori infection.\(^{25}\) Matveeva et al. reported that serum PGA and PGC levels of gastric ulcer patients were significantly increased along with changes of macrophages and cell-humoral balance.\(^{26}\) Animal experiments had shown that pepsin and pepsinogen are abundant in immune cells and plasma, and the production of interleukin-1 in vivo may be partially regulated by the plasma concentration of pepsin and pepsinogen.\(^{27}\) Hara et al. revealed that pepsinogen can bind nonspecifically to immune complexes and immunoglobulins.\(^{28}\)

### Table 1 (Continued)

| Pathway                           | Correlation coefficient |
|-----------------------------------|-------------------------|
|                                   | PGC         | PGA5         | PGA3         | PGA4         |
| HALLMARK_TGF_BETA_SIGNALING       | -0.08331    | -0.11723    | -0.11123    | -0.11492    |
| HALLMARK_TNF_SIGNALING_VIA_NFKB  | 0.097993    | 0.10124     | 0.095539    | 0.103767    |
| HALLMARK_UNFOLDED_PROTEIN_RESPONSE| -0.08318    | -0.16531    | -0.11658    | -0.08618    |
| HALLMARK_UV_RESPONSE_DN          | 0.111441    | 0.063833    | 0.042253    | 0.03483     |
| HALLMARK_UV_RESPONSE_UP          | -0.00555    | -0.06643    | -0.05887    | -0.03026    |
| HALLMARK_WNT_BETA_CATENIN_SIGNALING| 0.06264    | 0.012163    | 0.004281    | 0.0549      |
| HALLMARK_XENOBIOTIC_METABOLISM   | 0.289237    | 0.173161    | 0.191408    | 0.222242    |
### Table 2: Correlation between PGC expression and cancer-related pathways

| Pathway                             | Cancer type | R     | p value       |
|-------------------------------------|-------------|-------|---------------|
| ANDROGEN_RESPONSE                   | STAD        | 0.258346 | 5.26E-07     |
| BILE_ACID_METABOLISM                | STAD        | 0.307126 | 4.74E-08     |
| COAGULATION                         | STAD        | 0.259254 | 2.06E-05     |
| E2F_TARGETS                         | STAD        | −0.25135 | 4.94E-05     |
| ESTROGEN_RESPONSE_EARLY             | STAD        | 0.242907 | 0.000123     |
| G2M_CHECKPOINT                      | STAD        | −0.26701 | 8.43E-06     |
| KRAS_SIGNALING_DN                   | STAD        | 0.339758 | 3.70E-10     |
| MYC_TARGETS_V1                      | STAD        | −0.24327 | 0.000119     |
| PANCREAS_BETA.Cells                 | STAD        | 0.320524 | 6.95E-09     |
| XENOBIOTIC_METABOLISM               | STAD        | 0.289237 | 5.26E-07     |
| ADIPOGENESIS                        | ESCA        | −0.29456 | 0.000026     |
| APOPTOSIS                           | ESCA        | −0.34617 | 0.001699     |
| CHOLESTEROL_HOMEOSTASIS             | ESCA        | −0.2528  | 0.021382     |
| DNA_REPAIR                          | ESCA        | −0.34703 | 0.000122     |
| E2F_TARGETS                         | ESCA        | −0.28764 | 0.003607     |
| G2M_CHECKPOINT                      | ESCA        | −0.30326 | 0.001699     |
| HEME_METABOLISM                     | ESCA        | −0.35708 | 6.24E-05     |
| KRAS_SIGNALING_DN                   | ESCA        | 0.33191  | 0.000318     |
| MITOTIC_SPINDLE                     | ESCA        | −0.36193 | 4.47E-05     |
| MTORC1_SIGNALING                    | ESCA        | −0.30286 | 0.001699     |
| MYC_TARGETS_V1                      | ESCA        | −0.31736 | 0.000754     |
| MYC_TARGETS_V2                      | ESCA        | −0.29547 | 0.002536     |
| NOTCH_SIGNALING                     | ESCA        | −0.24232 | 0.032938     |
| OXIDATIVE_PHOSPHORYLATION           | ESCA        | −0.29483 | 0.00255      |
| P53_PATHWAY                         | ESCA        | −0.37275 | 2.07E-05     |
| PANCREAS_BETA.Cells                 | ESCA        | 0.306135 | 0.00147      |
| PEROXISOME                          | ESCA        | −0.36227 | 4.46E-05     |
| PI3K_AKT_MTOR_SIGNALING             | ESCA        | −0.33754 | 0.000223     |
| PROTEIN_SECRETION                   | ESCA        | −0.32454 | 0.00049      |
| SPERMATOGENESIS                     | ESCA        | −0.25025 | 0.023348     |
| TGF_BETA_SIGNALING                  | ESCA        | −0.35218 | 8.67E-05     |
| UNFOLDED_PROTEIN_RESPONSE           | ESCA        | −0.32859 | 0.000386     |
| WNT_BETA_CATENIN_SIGNALING          | ESCA        | −0.27507 | 0.06988      |
| ANGIogenesis                        | LUSC        | 0.363518 | 5.68E-17     |
| DNA_REPAIR                          | LUSC        | −0.33142 | 5.92E-14     |
| E2F_TARGETS                         | LUSC        | −0.33102 | 6.28E-14     |
| G2M_CHECKPOINT                      | LUSC        | −0.3295  | 8.38E-14     |
| GLYCOLYSIS                          | LUSC        | −0.37583 | 3.19E-18     |
| IL6_JAK_STAT3_SIGNALING             | LUSC        | 0.254868 | 4.38E-08     |
| INFLAMMATORY_RESPONSE               | LUSC        | 0.307018 | 6.68E-12     |
| MTORC1_SIGNALING                    | LUSC        | −0.3451  | 3.41E-15     |
| MYC_TARGETS_V1                      | LUSC        | −0.34399 | 4.24E-15     |
| MYC_TARGETS_V2                      | LUSC        | −0.34571 | 3.06E-15     |
| MYOGENESIS                          | LUSC        | 0.324046 | 2.48E-13     |

(Continues)
Combined the previous research with the results of our study, it is not hard to see that there is close relationship between PGs and tumor immune cell infiltration, which may provide a new idea for the research of tumor immunotherapy targeted PGs in the future.

The correlation analysis between PGs expression and prognosis in pan-cancer showed PGC was correlated with high survival rate of cancer patients in kidney renal clear cell carcinoma, acute myeloid leukemia, mesothelioma, and uveal melanoma. PGA5 was associated with good prognosis of cancer patients such as kidney renal clear cell carcinoma and kidney renal papillary cell carcinoma, while lung squamous cell carcinoma, prostate adenocarcinoma, and endometrial carcinoma are associated with poor prognosis of cancer patients. Previous studies have shown that PGC expression and tumor size are independent prognostic factors for overall survival and disease-free survival in hepatocellular carcinoma.29 PGC was also an important prognostic factor in predicting longer survival of patients with prostate adenocarcinoma.30 Our findings suggest that PGC and PGA5 had different effects on the prognosis of many kinds of cancers and they may be used as predictors of the prognosis in different cancers. It is worth pointing out that cancer prognosis was affected by many factors. In addition to consider the characteristics of the cancer itself, the role of the local microenvironment of the organs and tissues also should pay more attention, in which the cancer occurs. The balance of "seed and soil" determined the outcome of the cancer. The different prognostic role of PGs in different cancer indicates that it could play different potential in different tumor microenvironment. It is necessary to further explore the internal molecular mechanism of organ-specific prognostic role of PGs.

In our study, not only the parameters related to PGs expression were analyzed, but also the mutation and CNV of PGs were analyzed. The results showed that the overall average mutation rate of PGs was 0%-5.3%, and the mutation rate of

| Pathway                        | Cancer type | R       | p value   |
|-------------------------------|-------------|---------|-----------|
| OXIDATIVE_PHOSPHORYLATION     | LUSC        | -0.2636 | 1.16E-08  |
| P53_PATHWAY                   | LUSC        | -0.2720 | 3.06E-09  |
| PEROXISOME                    | LUSC        | -0.2962 | 4.75E-11  |
| UNFOLDED_PROTEIN_RESPONSE     | LUSC        | -0.3660 | 3.20E-17  |

**Figure 8** Correlation between PGs expression and immune cells infiltration. The genes in the outer circle represent genes within individual immune cells. Inner circles are formed by PGs. The size of each gene represents the number of connections.
PGC was higher in stomach adenocarcinoma and endometrial carcinoma. It is worth noticed that all PGC, PGA3, and PGA5 genes had a certain degree of mutation in endometrial carcinoma, which is a tumor with high global mutation rate. In addition, CCLE-based analysis of human cancer cell lines showed that most of the PGs mutations were found in colorectal adenocarcinoma and stomach adenocarcinoma cell lines, suggesting PGs mutation may be the key events in tumorigenesis and development of both gastric cancer and colorectal adenocarcinoma. In this study, we also found that there was extensive copy number amplification in various tumor types, which may be related to its widespread expression in various tissues. Furthermore, the effects of PGs mutation and CNV on PGs expression were analyzed in order to understand the influence of PGs inherent regulatory mechanism on PGs expression. The results showed that there was no correlation between PGs mutation and PGs expression in cancer cells. However, previous studies in our lab have found that PGC gene insertion-deletion fragment polymorphism and single nucleotide polymorphism from human germline cells can affect PGC expression. Both somatic gene mutations and germline cell polymorphisms are often base variation in DNA sequences, and key variation in gene structure often lead to changes in gene expression. Therefore, the findings of this study need to be further verified. In addition, we also analyzed the effect of PGs CNV on the gene expression and found that there was no correlation between PGA CNV and expression. In cholangiocarcinoma, esophageal cancer, and kidney renal papillary cell carcinoma, PGC expression was upregulated with the increase of copy number, but in stomach adenocarcinoma, both increase and deletion of PGC copy number could lead to the up-regulation of PGC expression. Studies have shown that the

![Figure 9](image-url)

**Figure 9** Prognostic significance associated with PGs expression. A, The correlation between PGs expression and cancer survival. Red color represents high risk of death while blue color represents low risk of death. B, Forest plot for the prognostic analysis of PGC across various cancer types.
increase in copy number was often matched with the upregulation of expression, but there are also some complex regulatory mechanisms existed, which make the correlation between CNV and gene expression very weak, sometimes even on the contrary. In some cancers, there may be transcriptional and posttranscriptional regulation, resulting in inconsistent changes in copy number and expression. For genes with increased copy number and decreased expression, there may be related noncoding RNA regulation to inhibit gene expression caused by CNV amplification. The mechanism of inhibition of expression needs to be further explored and verified, so that we will have a better understanding of CNV inhibition and enhanced bi-directional switching. In brief, genetic changes played a crucial part in the regulation of PGC expression. Its regulatory mechanism on the expression is worthy of our further study and exploration.

In conclusion, our study systematically demonstrated the expression profile of PG gene family as well as their activation pathways involved in human cancer. The relationship between PGs expression and clinical phenotypic characteristics was also explored from multi-angle. Moreover, the genetic variations of PGs own structure and their internal effects on the PGs expression was further elucidated. We found that PGs was expressed unevenly in a variety of cancer tissues and was related to many carcinogenic pathways.
and involved in the immune regulation. PGC participated in 33 regulatory pathways in pan-cancer. Different PGs expression play significantly different prognostic roles in different cancers. The variation of copy number of PGC gene could affect the PGC expression. These findings suggested that PGs, especially PGC have characteristic of broad-spectrum expression in multiple cancers rather than being confined to the gastric mucosa, which may made PGs be useful biomarkers for prediction/diagnosis/prognosis and effective targets for treatment in human cancer. Our study provides detailed and accurate analysis data for in-depth understanding of the relationship between PGs expression and phenotypic characteristics in human cancer and provide new clues for accurate diagnosis and treatment of PGs-target cancers.

| Cancer Type | CNV   | n   | Expression median value | p value |
|-------------|-------|-----|-------------------------|---------|
| CHOL        | DEL   | 3   | 0.003 (0.002-0.089)     | 0.022   |
|             | GAIN  | 10  | 0.048 (0.016-0.484)     |         |
|             | No Change | 23 | 0.006 (0.002-0.017)     |         |
| COAD        | DEL   | 31  | 0.017 (0.002-0.211)     | 0.383   |
|             | GAIN  | 96  | 0.025 (0.008-0.102)     |         |
|             | No Change | 321 | 0.018 (0.005-0.086)     |         |
| DLBC        | DEL   | 3   | 0.014 (0.008-0.015)     | 0.067   |
|             | GAIN  | 10  | 0.001 (0.001-0.002)     |         |
|             | No Change | 35 | 0.001 (0.0-0.002)       |         |
| ESCA        | DEL   | 25  | 0.004 (0-0.83)          | 0.017   |
|             | GAIN  | 56  | 0.305 (0.004-115.695)   |         |
|             | No Change | 79 | 0.027 (0.001-5.911)     |         |
| KICH        | DEL   | 50  | 0.002 (0.001-0.003)     | 0.759   |
|             | GAIN  | 2   | 0.018 (0.009-0.027)     |         |
|             | No Change | 13 | 0.003 (0-0.008)         |         |
| KIRP        | DEL   | 22  | 0.004 (0.001-0.043)     | <0.001  |
|             | GAIN  | 9   | 0.039 (0.025-0.181)     |         |
|             | No Change | 255| 0.001 (0-0.003)         |         |
| LAML        | GAIN  | 1   | 0.012 (0.012-0.012)     | 0.238   |
|             | No Change | 143| 0.003 (0.001-0.008)     |         |
| LIHC        | DEL   | 10  | 0.011 (0.001-0.549)     | 0.078   |
|             | GAIN  | 142 | 0.021 (0.001-0.485)     |         |
|             | No Change | 212| 0.002 (0-0.198)         |         |
| LUAD        | DEL   | 66  | 2.138 (0.194-20.508)    | 0.016   |
|             | GAIN  | 185 | 8.301 (0.666-211.746)   |         |
|             | No Change | 259| 8.296 (0.587-117.217)   |         |
| LUSC        | DEL   | 109 | 0.182 (0.005-1.905)     | 0.496   |
|             | GAIN  | 139 | 0.221 (0.007-2.326)     |         |
|             | No Change | 250| 0.34 (0.017-2.256)      |         |
| PRAD        | DEL   | 25  | 1.744 (0.288-16.542)    | 0.104   |
|             | GAIN  | 21  | 21.602 (0.506-43.134)   |         |
|             | No Change | 443| 6.554 (1.374-24.64)     |         |
| READ        | DEL   | 10  | 0.012 (0.004-0.045)     | 0.184   |
|             | GAIN  | 51  | 0.045 (0.013-0.119)     |         |
|             | No Change | 103| 0.028 (0.009-0.121)     |         |
| STAD        | DEL   | 34  | 47.186 (2.106-647.67)   | 0.032   |
|             | GAIN  | 101 | 67.936 (2.409-1399.045) | 0.020   |
|             | No Change | 239| 14.919 (0.448-530.709)  |         |

Bold values represents statistical significance when p is less than 0.05.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

AUTHORS’ CONTRIBUTION
Conceived and designed the experiments: Yuan Yuan and Liping Sun. Analyzed the data: Shixuan Shen, Hao Li, and Jingwei Liu. Wrote the paper: Shixuan Shen. Revised the manuscript: Yuan Yuan.

DATA AVAILABILITY STATEMENT
All the data come from TCGA, CCLE, and Oncomine databases. Other people could use these data.

ORCID
Yuan Yuan https://orcid.org/0000-0002-7394-9036

REFERENCES
1. Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530.
2. Marisa L, de Reyniès A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5):e1001453.
3. Youssef YM, White NMA, Grigull J, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol. 2011;59(5):721–730.
4. Hassan MI, Toor A, Ahmad F. Progastriscin: structure, function, and its role in tumor progression. J Mol Cell Biol. 2010;2(3):118-127.
5. Tu H, Sun L, Dong X, et al. A serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: a multi-phase study. Am J Gastroenterol. 2017;112(5):704-715.
6. Ning PF, Liu HJ, Yuan Y. Dynamic expression of pepsinogen C in gastric cancer, precancerous lesions and Helicobacter pylori associated gastric diseases. World J Gastroenterol. 2005;11(17):2545–2548.
7. Fostar C, Akter A, Kopf D, Zhang P, Guttag D. Pepsinogen C: a type 2 cell-specific protease. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L382-L387.
8. Antunes AA, Reis ST, Leite KR, et al. PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples. Int Braz J Urol. 2013;39(5):649-656.
9. Rojo JV, Merino AM, González LO, Vizoso F. Expression and clinical significance of pepsinogen C in epithelial ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol. 2002;104(1):58-63.
10. Serra Díaz C, Vizoso F, Rodríguez JC, et al. Expression of pepsinogen C in gynecomasias and male breast carcinomas. World J Surg. 1999;23(5):439-445.
11. Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569(7757):503-508.
12. Chin J, Shen S, Dong N, et al. Characterization of pepsinogen C and a series of phenotypic markers of gastric cancer in different gastric diseases. Cancer Med. 2018;7(8):4068-4076.
13. Melle C, Ernst G, Schimmel B, et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res. 2005;4(5):1799-1804.
14. Tenti P, Aguzzi A, Riva C, et al. Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreaticobiliary epithelial cells. Cancer. 1992;69(8):2131-2142.
15. Merino AM, Vázquez J, Rodríguez JC, et al. Pepsin C expression in tumors of extragastric origin. Int J Biol Markers. 2000;15(2):165-170.
16. Melle C, Ernst G, Schimmel B, et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res. 2005;4(5):1799-1804.
17. Serra Díaz C, Vizoso F, Rodríguez JC, et al. Expression of pepsinogen C in gynecomasias and male breast carcinomas. World J Surg. 1999;23(5):439-445.
18. Merino AM, Vázquez J, Rodríguez JC, et al. Pepsinogen C expression in tumors of extragastric origin. Int J Biol Markers. 2000;15(2):165-170.
19. Shen S, Jiang J, Yuan Y. Pepsinogen C expression, regulation and its role with relationship with cancer. Cancer Cell Int. 2017;17:57.
20. Mishchuk VH, Boichuk VB. Level of pepsin in patients with gastroesophageal reflux disease, Wiadomosci lekarskie (Warsaw, Poland : 1960). 2014;67(2 Pt 2):356-358.
21. Samuels TL, Altman KW, Gould JC, et al. Esophageal pepsin and proton pump synthesis in barrett’s esophagus and esophageal adenocarcinoma. The Laryngoscope. 2012;19(12):2687-2695.
22. Rosen R, Johnston N, Hart K, Khatwa U, Nunko S. The presence of pepsin in the lung and its relationship to pathologic gastro-esophageal reflux. Neurogastroenterol Motil. 2012;24(2):129-133, e84-85.
23. Starosta V, Kitz R, Hartl D, Marcos V, Reinhardt D, Griese M. Bronchoalveolar pepsin, bile acids, oxidation, and inflammation in children with gastroesophageal reflux disease. Chest. 2007;132(5):1557-1564.
24. Hurley BP, Jugo RH, Snow RF, et al. Pepsin triggers neutrophil migration across acid damaged lung epithelium. Sci Rep. 2019;9(1):13778.
25. Al-Ezzi IA. Immunopathological and Modulatory Effects of Cag A(+) Genotype on Gastric Mucosa, Inflammatory Response, Pepsinogens, and Gastrin-17 Secretion in Iraqi Patients infected with H pylori. Open Access Maced J Med Sci. 2018;6(5):794-802.
26. Matveeva LV, Mosina LM. Interrelation secretory activity of stomach and immune changes of peripheral blood when ulcerogenesis stomach. Patol Fiziol Eksp Ter. 2016;60(5):72-78.
27. Lyte M. Regulation of interleukin-1 production in murine macrophages and human monocytes by a normal physiological constituent. Life Sci. 1986;38(13):1163–1170.
28. O’Hara BP, Pyle J, McCarthy D, Archer JR, Binding of monomeric and aggregated immunoglobulin to enzymes. A source of artefact in antibody assays. J Immunol Methods. 1989;116(2):175-179.
29. Chen H, Zhu HR, Yu XN, et al. Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study. Cancer Manag Res. 2019;11:2927-2934.
30. Díaz M, Rodríguez JC, Sánchez J, et al. Clinical significance of pepsinogen C tumor expression in patients with stage D2 prostate carcinoma. Int J Biol Markers. 2002;17(2):125-129.
31. Rutgers JK. Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma. *Future Oncol*. 2015;11(23):3207-3218.
32. Sun LP, Gong YH, Dong NN, Wang L, Yuan Y. Correlation of pepsinogen C (PGC) gene insertion/deletion polymorphism to PGC protein expression in gastric mucosa and serum. *Ai Zheng*. 2009;28(5):487-492.
33. Almal SH, Padh H. Implications of gene copy-number variation in health and diseases. *J Hum Genet*. 2012;57(1):6-13.
34. Han S, Zou H, Lee J-W, et al. miR-1307-3p stimulates breast cancer development and progression by targeting SMYD4. *J Cancer*. 2019;10(2):441-448.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Shen S, Li H, Liu J, Sun L, Yuan Y. The panoramic picture of pepsinogen gene family with pan-cancer. *Cancer Med*. 2020;9:9064–9080. [https://doi.org/10.1002/cam4.3489](https://doi.org/10.1002/cam4.3489)